Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
出版年份 2021 全文链接
标题
Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
作者
关键词
-
出版物
Infectious Diseases and Therapy
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-08-28
DOI
10.1007/s40121-021-00517-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021
- (2021) Summer E. Galloway et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome
- (2021) Koichiro Suemori et al. PLoS Neglected Tropical Diseases
- Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients
- (2021) Satoshi Fujii et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
- (2021) Sandile Cele et al. NATURE
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
- (2020) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Virological assessment of hospitalized patients with COVID-2019
- (2020) Roman Wölfel et al. NATURE
- Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young
- (2020) Thomas J. Oxley et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
- (2020) Qianqian Li et al. CELL
- A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19
- (2020) Yohei Doi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
- (2020) Suzanne J. F. Kaptein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis
- (2020) Ashleigh Shannon et al. Nature Communications
- Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment
- (2020) Yan Wang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Clinical Features of 154 COVID-19 Patients and the Parameters for the Effective Detection of Pneumonia at the Time of the Initial Diagnosis in Japan
- (2020) Miwa Morikawa et al. INTERNAL MEDICINE
- Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
- (2020) Zarir F. Udwadia et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a Model of Arenavirus Hemorrhagic Fever
- (2011) Michelle Mendenhall et al. PLoS Neglected Tropical Diseases
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now